Profusa, Inc.

Profusa, Inc. (Nasdaq: PFSA) is a medical technology company focused on implantable biosensor technology designed to enable continuous, real-time monitoring of tissue biochemistry, operating within the healthcare and biotechnology sector. The company filed a 424B4 final prospectus with the SEC on December 22, 2021, marking its entry into the public markets through a SPAC transaction. Profusa's platform centers on injectable, hydrogel-based sensors intended to provide persistent physiological data, with applications spanning metabolic health and military readiness monitoring. The company's public listing via SPAC reflects broader 2021 enthusiasm for digital health and continuous monitoring technologies. For full filing history, investor details, and real-time deal tracking on PFSA and hundreds of other SPAC transactions, sign up for SpacDesk at spacdesk.com.